Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- December15 2003
- Volume 10
- Issue 23
Some Market Insights
Author(s)Michael Sheehan
Advertisement
If you've been tracking the mutualfund scandal and you're confused aboutwhat's illegal and what's merely unethical,pay a visit to TheStreet.com, whereBeverly Goodman's concise analysis canhelp clarify the issues. Founded by financialTV host Jim Cramer, TheStreet offersdaily stock news and analysis, as well asa premium site that features online chatswith the site's contributors. For basicfinancial news and personal finance tips,try CBS MarketWatch (www. cbs.marketwatch.com). The site provides adviceon retirement planning, buying realestate, and investing in general, alongwith an in-depth dose of market news.Best of all, MarketWatch's informationis completely free.
Articles in this issue
about 18 years ago
Prevent Vacation Home Flood Calamitiesabout 18 years ago
Get the Attention of Top Money Managersabout 18 years ago
Is Your Medical Practice in Jeopardy?about 18 years ago
10 Web Site Tips to Improve Your Practiceabout 18 years ago
Should You Be Concerned with the AMT?about 18 years ago
Wealth Preservation: Protect Your Treasuresabout 18 years ago
Other Valuable Toolsabout 18 years ago
Make Sense of the Mutual Fund Scandalabout 18 years ago
Survive the Mutual Fund Fiascoabout 18 years ago
Discover the Scandal Behind the ScandalAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5